Critical Appraisal of Artificial Intelligence for Rare-Event Recognition: Principles and Pharmacovigilance Case Studies [0.03%]
人工智能罕见事件识别的批判性评价：原理与药品不良反应监测案例研究
G Niklas Norén,Eva-Lisa Meldau,Johan Ellenius
G Niklas Norén
Many high-stakes artificial intelligence (AI) applications target low-prevalence events, where apparent accuracy can conceal limited real-world value. Relevant AI models range from expert-defined rules and traditional machine learning to ge...
Maternal and Pediatric Use of Vaccines for Mpox: A Living Systematic Review and Meta-analysis of Safety and Effectiveness [0.03%]
母体和儿童接种猴痘疫苗的使用：安全性和有效性的living系统评价和meta分析
Agustín Ciapponi,Jamile Ballivian,Mabel Berrueta et al.
Agustín Ciapponi et al.
Background: Mpox is a re-emerging zoonotic infection caused by an Orthopoxvirus closely related to smallpox. The 2022-23 global outbreak prompted rapid use of vaccinia-based vaccines, historically developed for smallpox a...
Correction: Assessing the Use of Medical Insurance Claims and Electronic Health Records to Measure COVID‑19 Vaccination During Pregnancy [0.03%]
关于使用医疗保险索赔和电子健康记录衡量怀孕期间的COVID-19疫苗接种情况的评估（勘误）
Matthew M Coates,Stacey L Rowe,Sheena G Sullivan et al.
Matthew M Coates et al.
Published Erratum
Drug safety. 2026 Mar 6. DOI:10.1007/s40264-026-01661-x 2026
Xu Steven Xu,Kinjal Sanghavi,Summer Feng et al.
Xu Steven Xu et al.
Antibody-drug conjugates (ADCs) have emerged as an important therapeutic class in oncology, offering targeted delivery of potent cytotoxic agents to cancer cells, thereby reducing systemic toxicity. However, the potential for cardiac toxici...
Genetically Informed Research Designs in Perinatal Pharmacoepidemiology: A Methodological Overview [0.03%]
孕产期药物流行病学中的遗传性研究设计：方法综述
Alexis C Carson,Mahmoud Zidan,Emilie Willoch Olstad et al.
Alexis C Carson et al.
Despite the widespread use of medications during pregnancy, ethical and methodological barriers to clinical trials make observational studies necessary for evaluating medication safety in this population. Observational studies are prone to ...
The Evaluation of Transformer Models for the Detection of Adverse Drug Events: A Benchmark Study Using Dutch Free-Text Documents of Hospitalized Patients [0.03%]
基于荷兰住院患者自由文本的药物不良事件检测基准研究
Rachel M Murphy,Nishant Mishra,Nicolette F de Keizer et al.
Rachel M Murphy et al.
Introduction: Adverse drug events (ADEs) are a leading cause of preventable patient harm in hospitals. Because they are often recorded only in clinical free-text documents, retrieval and quantification are significantly l...
NSAIDs Use During Herpes Zoster Infection and Stroke Risk: A Nationwide Case-Crossover Study [0.03%]
带状疱疹感染期使用非甾体抗炎药与卒中风险的关系——一项全国性病例交叉研究
Lin-Chieh Meng,Hsi-Yu Lai,Hui-Min Chuang et al.
Lin-Chieh Meng et al.
Background and aims: Herpes zoster (HZ) infection and long-term non-steroidal anti-inflammatory drugs (NSAIDs) use are established risk factors for stroke and other cardiovascular diseases. Given the paucity of evidence r...
Pharmacovigilance Through Fresh Eyes: The International Society of Pharmacovigilance Student Community's Role in Shaping the Future of Pharmacovigilance [0.03%]
焕然一新的药物警戒观：国际药物警戒学生社团在塑造药物警戒未来中所起的作用
Hager Saleh,Ibrahim Mohammed Amidu,Zerin Ziaudeen et al.
Hager Saleh et al.
Editorial
Drug safety. 2026 Feb 12. DOI:10.1007/s40264-026-01651-z 2026
VigiBase: Resource Profile Update with a Summary of Global Patterns and Trends in Adverse Event Reports for Medicines and Vaccines [0.03%]
VigiBase：药品和疫苗不良事件报告的全球格局与趋势概要及资源档案更新
Judith S Brand,Oskar Gauffin,Daniele Sartori et al.
Judith S Brand et al.
VigiBase, the WHO global database of adverse event reports for medicines and vaccines, receives information on suspected adverse effects of medicinal products from countries, regions and territories that are members of the WHO Programme for...
Physician Awareness of FDA's Relaxation of REMS-Required Laboratory Testing Requirements and Changes in Prescribing Practices During the COVID-19 Pandemic [0.03%]
新冠肺炎大流行期间FDA关于降低REMS要求的实验室检测要求的意识变化和处方习惯的变化
Catherine S Hwang,Zhigang Lu,Massimiliano Russo et al.
Catherine S Hwang et al.
Background: The US Food and Drug Administration (FDA) requires pharmaceutical manufacturers to implement Risk Evaluation and Mitigation Strategy (REMS) programs for certain medications that carry serious safety risks. One...